A Phase 2a, Randomized, Double-Blind, Active-Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD)
El propósito de este ensayo de prueba de concepto es evaluar la seguridad, la tolerabilidad, la farmacocinética (PK) y la eficacia clínica preliminar de CYB004 en participantes con GAD.
- Status
- active
- Phase
- Phase 2
- Institution
- Cybin IRL Limited
- Principal investigator
- Amir Inamdar, MBBS, DNB, MFPM
- Start date
- 2024-05-10
- End date
- 2026-09-01
- Registry ID
- NCT06051721
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.